AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024
October 17, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and pre-clinical...
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies
September 25, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AskBio and Belief BioMed will work together to advance potential gene...
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
August 02, 2024 07:20 ET
|
Arch Biopartners
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique...
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
July 11, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment of...
Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
May 29, 2024 13:46 ET
|
Lynch Carpenter
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of 2024, which impacted the personal information...
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024
May 02, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG,...
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
April 18, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is being studied for the treatment of adults with non-ischemic...
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
April 16, 2024 08:03 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
AskBio Names Mansuo Shannon Chief Scientific Officer
April 09, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyCo-Founder and former Chief...
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
February 13, 2024 08:10 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is an investigational gene therapy for the treatment of adults with...